Materials • Major Chemicals
$93.02 ▲ +2.21
(+2.43%)
MKT CAP: $23.17B • VOL: 2.72M
52W L $61 52W H $95
IFF // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $10.89B | $11.48B | $11.48B |
| YoY Revenue Growth % | -5.2% | 0.0% | — |
| Gross Profit | $3.94B | $4.12B | — |
| Gross Margin % | 36.2% | 35.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$382.0M | $766.0M | -$2.11B |
| Operating Margin % | -3.5% | 6.7% | -18.4% |
| Net Income (GAAP) | $0 | $0 | $0 |
| EBITDA (Normalized) | $93.2M | $1.14B | -$1.70B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $850.0M | $1.07B | $1.46B |
| Capital Expenditures (CapEx) | $594.0M | $463.0M | $516.6M |
| Free Cash Flow (FCF) | $256.0M | $607.0M | $938.4M |
| FCF Margin % | 2.4% | 5.3% | 8.2% |
| Return on Invested Capital (ROIC %) | -1.6% | 2.9% | -20.0% |
| Cash & Short-Term Equivalents | $590.0M | $469.0M | — |
| Total Debt (Short + Long Term) | $4.74B | $7.56B | $3.22B |
| Total Stockholders' Equity | $14.15B | $13.83B | $6.61B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IFF.